Anagrelid

G. Birgegard, M. Björkholm, J. Kutti, G. Lärfars, E. Löfvenberg, B. Markevärn

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders  

Haematologica 2004; 89: 520-527

A. Emadi, J. L. Spivak

Anagrelide: 20 years later 

Expert Rev.Anticancer Ther.2009; 9(1): 37-50

H. Gisslinger, M. Gotic, J. Holowiecki, M. Penka, J.Thiele, H-M. Kvasnicka

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial   

Blood 2013; 121(10): 1720-1728

C. N. Harrison,P. J. Campbell, G.Buck, K. Wheatley, C. L. East, D. Bareford

Hydroxyurea Compared with Anagrelide in high-risk Essential Thrombocythemia  

The New England Journal of Medicine 2005; 353: 33-45

M. G. Mazzucconi, R. Redi ,S. Bernasconi, L. Bizzoni, F. Dragoni, R. Latagliata

A long-therm study of young patients with essential thrombocythemia treated with anagrelide 

Haematologica 2004; 89: 1306-1313

P. E. Petrides

Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia

Expert Opinion Pharmacother. 2004 5(8): 1781-1798

M. Steurer, G. Gastl, W-W.Jedrzejczak, R. Pytlik, W. Lin, E. Schlögl

Anagrelide for Thrombocytosis in Myeloproliferative  Disorders 

Cancer 2004; 101: 2239–46.

A. J. Wagstaff, G. M. Keating

Anagrelide A review of its use in the Management  of Essential Thrombocythaemia   

Drugs 2006; 66 (1): 111-131